Evercore ISI Raises Price Target on Mirum Pharmaceuticals to $66 From $62, Keeps Outperform Rating
Morgan Stanley Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)
Optimistic Buy Rating for Mirum Pharmaceuticals Amidst Strong Sales Growth and Expanded LIVMARLI Label
Mirum Pharmaceuticals (MIRM) Receives a Buy From Evercore ISI
Mirum Pharmaceuticals Price Target Raised to $66.00/Share From $62.00 by Evercore ISI Group
Mirum Pharmaceuticals Analyst Ratings
Mirum Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $66
Buy Rating Affirmed for Mirum Pharmaceuticals Amidst Label Expansion and Positive EU Authorization
JMP Securities Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $69
Mirum Pharmaceuticals (MIRM) Gets a Buy From JMP Securities
Buy Rating Justified: Mirum Pharmaceuticals' Growth Prospects and Market Expansion Post-Livmarli Approval
Mirum Pharmaceuticals Analyst Ratings
Buy Rating Affirmed for Mirum Pharmaceuticals on LIVMARLI's EU Approval and Positive Revenue Projections
Mirum Pharmaceuticals Analyst Ratings
JMP Securities Adjusts Price Target on Mirum Pharmaceuticals to $68 From $66, Maintains Market Outperform Rating
Mirum Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Adjusts Price Target on Mirum Pharmaceuticals to $50 From $45, Maintains Overweight Rating
Mirum Pharmaceuticals Analyst Ratings
Mirum Pharmaceuticals Analyst Ratings